Theriva Biologics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $300KTTM through 31 Mar 2026
Net Income -$21.4MTTM through 31 Mar 2026
Free Cash Flow -$16.2MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Operating Margin | -709.0% |
| Net Margin | -681.3% |
Returns
-139.1%ROE
-56.0%ROA
Balance Sheet Health
Debt / Equity0.11x
Current Ratio1.63x
Net Debt-$12.8Mnet cash position
Cash & Equivalents$14.4M
Quality Metrics
FCF Margin-5,385.3%
Earnings-Beat Rate0.0%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Theriva Biologics Consolidated | $300K | View detailsR&D expenses are expected to decrease in 2026 due to the completion of the VIRAGE Phase 2b trial and a workforce reduction implemented in late 2025, but will rise again as new clinical trials commence. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.